OptimizeRx (NASDAQ:OPRX) Receives Buy Rating from Lake Street Capital

Lake Street Capital reissued their buy rating on shares of OptimizeRx (NASDAQ:OPRX) in a research note issued to investors on Tuesday morning,Benzinga reports. They currently have a $11.00 price objective on the stock.

Other equities research analysts also recently issued research reports about the company. Stephens initiated coverage on OptimizeRx in a report on Friday, December 20th. They issued an “equal weight” rating and a $5.50 target price for the company. Barclays cut their target price on shares of OptimizeRx from $11.00 to $5.00 and set an “equal weight” rating for the company in a research note on Thursday, November 14th. B. Riley dropped their price objective on shares of OptimizeRx from $17.00 to $13.00 and set a “buy” rating for the company in a research note on Tuesday. Roth Mkm restated a “buy” rating and issued a $16.00 target price (down from $20.00) on shares of OptimizeRx in a report on Thursday, November 14th. Finally, JMP Securities decreased their price target on shares of OptimizeRx from $16.00 to $8.00 and set a “market outperform” rating on the stock in a report on Thursday, November 14th. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $9.19.

OptimizeRx Trading Up 2.3 %

Shares of OPRX stock opened at $4.94 on Tuesday. OptimizeRx has a twelve month low of $3.78 and a twelve month high of $16.65. The company has a market capitalization of $91.00 million, a P/E ratio of -3.71 and a beta of 1.34. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 0.29. The business’s 50 day moving average is $5.31 and its two-hundred day moving average is $7.69.

Insider Buying and Selling

In other news, CEO William J. Febbo purchased 20,000 shares of the stock in a transaction dated Thursday, December 12th. The stock was acquired at an average price of $5.01 per share, for a total transaction of $100,200.00. Following the completion of the transaction, the chief executive officer now owns 601,253 shares of the company’s stock, valued at approximately $3,012,277.53. The trade was a 3.44 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 6.10% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets grew its holdings in shares of OptimizeRx by 189.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 3,690 shares of the company’s stock worth $28,000 after acquiring an additional 2,414 shares during the last quarter. Quest Partners LLC lifted its stake in OptimizeRx by 15,965.6% during the third quarter. Quest Partners LLC now owns 9,800 shares of the company’s stock valued at $76,000 after buying an additional 9,739 shares in the last quarter. Connors Investor Services Inc. raised its holdings in shares of OptimizeRx by 15.1% during the second quarter. Connors Investor Services Inc. now owns 19,107 shares of the company’s stock valued at $191,000 after acquiring an additional 2,500 shares during the period. Barclays PLC boosted its stake in OptimizeRx by 358.5% in the 3rd quarter. Barclays PLC now owns 26,934 shares of the company’s stock worth $208,000 after purchasing an additional 21,060 shares during the period. Finally, Squarepoint Ops LLC purchased a new position in OptimizeRx during the 2nd quarter worth approximately $282,000. Institutional investors and hedge funds own 76.47% of the company’s stock.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.